Nair J, Huang TT, Murai J, Haynes B, et al. Resistance to the CHK1 inhibitor prexasertib involves functionally distinct CHK1 activities in BRCA wild-type ovarian cancer. Oncogene 2020 Jul 9. pii: 10.1038/s41388-020-1383.
PMID: 32647134